BioNTech, Bristol Myers Squibb Announced Sunday At ESMO, Phase 2 ROSETTA Lung-107 Data Showing Pumitamig + Docetaxel Achieved 36.7% Confirmed Objective Response Rate, 90% Disease Control Rate, 6.9-Month Median PFS In Previously Treated Metastatic NSCLC

Loading news article.

BioNTech, Bristol Myers Squibb Announced Sunday At ESMO, Phase 2 ROSETTA Lung-107 Data Showing Pumitamig + Docetaxel Achieved 36.7% Confirmed Objective Response Rate, 90% Disease Control Rate, 6.9-Month Median PFS In Previously Treated Metastatic NSCLC | WAPE

BioNTech, Bristol Myers Squibb Announced Sunday At ESMO, Phase 2 ROSETTA Lung-107 Data Showing Pumitamig + Docetaxel Achieved 36.7% Confirmed Objective Response Rate, 90% Disease Control Rate, 6.9-Month Median PFS In Previously Treated Metastatic NSCLC

Article summary

Related companies

Comments —